1.65

14.51% -0.28

Pre-market: 1.54 -0.11 -6.67%

Telomir Pharmaceuticals Inc (TELO)

Overview News Price History Discussions Forecast

Telomir Pharmaceuticals Inc stock is traded at $1.65, with a volume of 2.72M. It is down -14.51% in the last 24 hours and up +30.95% over the past month. Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.

Previous Close:

$1.93

Open:

$1.79

24h Volume:

2.72M

Relative Volume:

0.56

Market Cap:

$53.26M

Revenue:

Net Income/Loss:

$-16.14M

P/E Ratio:

-3.0556

EPS:

-0.54

Net Cash Flow:

$-3.99M

1W Performance:

+17.86%

1M Performance:

+30.95%

6M Performance:

-37.74%

1Y Performance:

-67.00%

1-Day Range:

$1.60

$1.8172

1-Week Range:

$1.37

$2.091

52-Week Range:

$1.12

$7.0791

Telomir Pharmaceuticals Inc Stock (TELO) Company Profile

Name

Telomir Pharmaceuticals Inc

Sector

Healthcare (1140)

Industry

Biotechnology (637)

Phone

786-396-6723

Address

100 SE 2ND ST, MIAMI

Employee

Twitter

Next Earnings Date

2025-09-03

Latest SEC Filings

TELO's Discussions on Twitter

Compare TELO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TELO Telomir Pharmaceuticals Inc	1.65	65.29M	0	-16.14M	-3.99M	-0.54
VRTX Vertex Pharmaceuticals Inc	407.79	106.37B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	460.46	59.90B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	564.63	60.40B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	796.92	49.56B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.10	36.88B	4.56B	-176.77M	225.30M	-1.7177

Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-21-25	Initiated	Rodman & Renshaw	Buy

Telomir Pharmaceuticals Inc Stock (TELO) Latest News

03:42 AM

Tools to assess Telomir Pharmaceuticals Inc.’s risk profileWeekly Risk Report & AI Forecasted Entry and Exit Points - newser.com

03:42 AM

03:13 AM

What to do if you’re stuck in Telomir Pharmaceuticals Inc.July 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com

03:13 AM

Oct 12, 2025

Why Telomir Pharmaceuticals Inc. is moving todayMarket Rally & Free Community Supported Trade Ideas - newser.com

Oct 12, 2025

Telomir Pharmaceuticals Inc Stock Analysis and ForecastLong-Term Investment Plans & Download Our Free Trading Blueprint - earlytimes.in

Oct 12, 2025

Oct 11, 2025

What drives Telomir Pharmaceuticals Inc stock priceIndustrial Stocks Review & Free Transform Portfolio With Stocks - earlytimes.in

Oct 11, 2025

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Re - Shreveport Times

Oct 11, 2025

Oct 10, 2025

Why Telomir Pharmaceuticals Stock Is Rising 40% Premarket Today - Stocktwits

Oct 10, 2025

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells - DelmarvaNow.com

Oct 10, 2025

Institutional scanner results for Telomir Pharmaceuticals Inc.2025 Fundamental Recap & Risk Controlled Stock Alerts - newser.com

Oct 10, 2025

How to monitor Telomir Pharmaceuticals Inc. with trend dashboardsJuly 2025 Trade Ideas & Daily Chart Pattern Signal Reports - newser.com

Oct 10, 2025

Oct 09, 2025